NCT01771107 · REGISTRY CONDITION SEARCH

Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE1, PHASE2
Status at capture: COMPLETED
Registry last update: 2025-08-15

This pilot phase I/II trial studies the side effects and the best dose of brentuximab vedotin when given together with combination chemotherapy and to see how well they work in treating patients with stage II-IV human immunodeficiency virus (HIV)-associated Hodgkin lymphoma. Brentuximab vedotin is a monoclonal antibody, called brentuximab, linked to a chemotherapy drug called vedotin. Brentuximab attaches to CD30-positive cancer cells in a targeted way and delivers vedotin to kill them. Drugs used in chemotherapy, such as doxorubicin hydrochloride, vinblastine sulfate, and dacarbazine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving brentuximab vedotin together with combination chemotherapy may kill more cancer cells.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Maximal Tolerated Dose of Brentuximab Vedotin (Phase I)

→

outcome · POSTED

2-year Progression-free Survival (PFS) (Phase II)

→

outcome · POSTED

Frequency of Adverse Events

→

outcome · POSTED

Partial Response Rate

→

outcome · POSTED

Partial Response Rate

→

outcome · POSTED

Complete Response Rate

→

outcome · POSTED

Complete Response Rate

→

outcome · POSTED

2-year Overall Survival

→

outcome · POSTED

Overall Survival

→

outcome · POSTED

Event-free Survival

→

outcome · POSTED

Event-free Survival

→

outcome · POSTED

CD4 Counts

→

outcome · POSTED

CD8 Counts

→

outcome · POSTED

Viral Load

→

outcome · POSTED

Prognostic Value of Fludeoxyglucose F-18 (FDG)-Positron Emission Tomography (PET) in Patient With HIV and Hodgkin Lymphoma (HL) With Respect to 2 Year Progression Free Survival

→

outcome · POSTED

Prognostic Value of FDG-PET in Patient With HIV and HL With Respect to 2 Year Progression Free Survival

→

outcome · POSTED

Prognostic Value of FDG-PET in Patient With HIV and HL With Respect to 2 Year Progression Free Survival

→

outcome · POSTED

HAART Status

→

outcome · POSTED

HAART Status

→

outcome · POSTED

Characterization of Histologic Subtypes in HIV-HL in the HAART Era

→

outcome · POSTED

Incidence of Neurotoxicity

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria: * HIV positive; documentation of HIV-1 infection by means of any one of the following: * Documentation of HIV diagnosis in the medical record by a licensed health care provider; * Documentation of receipt of antiretroviral therapy (ART) by a licensed health care provider; * HIV-1 RNA detection by a licensed HIV-1 RNA assay demonstrating \> 1000 RNA copies/mL; * Any licensed HIV screening antibody and/or HIV antibody/antigen combination assay confirmed by a second licensed HIV assay such as a HIV-1 western blot confirmation or HIV rapid multispot antibody differentiation assay * NOTE: A "licensed" assay refers to a United States (US) Food and Drug Administration (FDA)-approved assay, which is required for all investigational new drug (IND) studies * Histologic diagnosis of CD30-positive classical HL as defined by the 2008 World Health Organization (WHO) Classification of Hematological diseases; nodular lymphocyte predominant Hodgkin lymphoma is not eligible * Stage II, III or IV disease as defined by the Ann Arbor Staging System * Participants must have previously untreated HIV-classical HL (cHL), with the exception of up to 14 consecutive days of steroids, emergency radiation, or 1 prior cycle of cyclophosphamide to reduce tumor burden and improve hyperbilirubinemia in the setting of lymphoma related liver involvement * Normal baseline cardiac ejection fraction \>= 50% * Serum creatinine of =\< 1.5 mg/dL; if creatinine \> 1.5 mg/dL, creatinine clearance must be \>= 60 mL/minute * Absolute neutrophil count (ANC) \>= 1000/uL * Platelets \>= 75,000/uL unless related to bone marrow involvement by HIV-cHL * Total bilirubin must be \< 1.5 x the upper limit of normal, unless the elevation of bilirubin is thought to be secondary to Gilbert's syndrome or combined antiretroviral therapy (cART); if, however, the elevated bilirubin is felt to be secondary to antiretroviral therapy, the total bilirubin must be =\< 3.5 mg/dL, provided that the direct bilirubin is normal and the aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\< 3 x the upper limit of normal; also, if the elevated bilirubin is thought to be secondary to cHL the same criteria for hyperbilirubinemia should be applied; however 1 prior cycle of cyclophosphamide is permitted in attempt to make the participant eligible; patients should not be excluded from study participation unless dosing cannot be safely established * Female participants must have a negative pregnancy test within 1 week of enrollment and all participants must agree to use two reliable methods of contraception simultaneously if conception is possible during the study and for 6 months after stopping treatment; should a woman subject become pregnant or suspect she is pregnant while the subject is participating in this study, she should inform her treating physician immediately; the participant will then be removed from protocol therapy; participants who father a child while participating in the study will be permitted to continue with the protocol; the participant, however, is required to notify the investigator if he fathers a child * Ability to understand and the willingness to sign a written informed consent document * Karnofsky performance status \> 30% (given the aggressiveness of this disease and the often severely debilitated nature of the patients at initial presentation) * Measurable or non-measurable (evaluable) tumor parameter(s); non-measurable tumor parameters will be defined as not having bi-dimensional measurements (i.e., gastric or marrow involvement) but can be followed for response by other diagnostic tests such as gallium, PET imaging and/or bone marrow biopsy * Patients already receiving erythropoietin or granulocyte colony stimulating factor (GCSF) for treatment of HIV-related cytopenia are eligible * CD4 count \>= 50 cells/ul * Participants are required to be on antiretroviral regimens that are in accordance with the current International Acquired Immune Deficiency Syndrome (AIDS) Society guidelines concurrently with chemotherapy; the specific agents are at the discretion of the investigator and the use of investigational agents currently available on an expanded access basis is allowed; use of experimental antiretroviral agents or those containing zidovudine (including Combivir and Trizivir) or ritonavir (includes Norvir or Kaletra), cobicistat, didanosine (Videx or Videx EC), or similar potent cytochrome P450 (CYP)3 inhibitors are prohibited; in order to be eligible, participants taking zidovudine or ritonavir, or cobicistat, didanosine, or other CYP3 inhibitors must change to a different regimen 7 days prior to therapy initiation; changes to HAART therapy during the study may be made if medically necessary (toxicity, failure of regimen, etc.); participants must be on HAART at least 7 days prior to therapy * Negative for hepatitis B, or if infected with hepatitis B, receiving anti-hepatitis B therapy; all participants will be required to be screened for hepatitis B; per Infectious Disease Society of America (IDSA) and Assistance for AIDS Specific Drugs (AASD) guidelines, those participants that show no immunity, defined by the lack of hepatitis B surface antigen antibody, and show evidence of chronic infection (i.e. hepatitis B surface antigen \[HBsAg\]+, hepatitis B core \[HBcore\]+, hepatitis B surface antibody \[HBsAB\]-) will be required to be on anti-hepatitis B therapy during the study in order to be eligible; patients will be permitted to enroll in the study provided normal liver function tests and no evidence of cirrhosis; the exact hepatitis B therapy will be at the discretion of the infection disease specialist or investigator; however all patients who present with acute hepatitis B or show normal transaminases and are hepatitis B virus HBsAg surface protein antigen (HBsAg) positive (+) and immunoglobulin M (IgM)+ for hepatitis core antigen will not be eligible for trial enrollment * Patients diagnosed with hepatitis C who are hepatitis C antibody positive, whether hepatitis C RNA level is measurable or not, must have no evidence of cirrhosis and have liver function tests * Brentuximab vedotin is partially metabolized via the CYP3A4 pathway and is cleared from the cells via the P-glycoprotein pump; therefore, participants must discontinue use of the following agents within 7 days prior to therapy * Strong CYP3A4 inhibitors that treat HIV * Other strong CYP3A inhibitors * Moderate CYP3A4 inhibitors should be used with caution but are not excluded; if 2 moderate CYP3A4 inhibitors are used concurrently, one must be discontinued at least 7 days (1 week) prior to the initiation of chemotherapy * P-glycoprotein inhibitors * If patients are taking any of these excluded medications, they must be discontinued at least 7 days (1 week) prior to the initiation of chemotherapy All concomitant medications must be reviewed by the study chair or co-chair prior to enrollment by email; because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated medical reference for a list of drugs to avoid or minimize use of Exclusion Criteria: * Patients with prior anthracycline therapy will be excluded * Female participants who are pregnant or breast-feeding; confirmation that the subject is not pregnant must be established by a negative serum beta (b)-human chorionic gonadotropin (b-hCG) or urine pregnancy test result obtained during screening; pregnancy testing is not required for post-menopausal or surgically sterilized women * Medical illness unrelated to HL, which in the opinion of the study physician will preclude administration of chemotherapy safely; this includes patients with uncontrolled infection (including opportunistic), chronic renal failure, myocardial infarction (MI) within the past 6 months, unstable angina, or cardiac arrhythmias other than chronic atrial fibrillation, or second malignancy requiring active treatment * Prior malignancy within 2 years before enrollment other than curatively treated cutaneous basal cell or squamous cell carcinoma, carcinoma in situ of the cervix, anal intraepithelial neoplasia, or cutaneous Kaposi's sarcoma (KS); participants with prior malignancies must have completed all therapy at least 2 years before enrollment with no evidence of disease since therapy completion * Grade 2 or greater peripheral neuropathy * Evidence of progressive multifocal leukoencephalopathy (PML) identified on the pretreatment magnetic resonance imaging (MRI) * Central nervous system disease * Patients with history of John Cunningham (JC) virus identified in the cerebrospinal fluid (CSF) or previous history of PML will be excluded from the study * Cirrhosis secondary to any cause will be excluded
healthy Volunteers: false
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
Patients receive doxorubicin hydrochloride IV, vinblastine sulfate IV, and dacarbazine IV on days 1 and 15. Patients also receive brentuximab vedotin IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
intervention Names
Drug: Brentuximab Vedotin
Drug: Dacarbazine
Drug: Doxorubicin Hydrochloride
Other: Pharmacological Study
Drug: Vinblastine
label
Treatment (brentuximab and combination chemotherapy)
type
EXPERIMENTAL

interventions

arm Group Labels
Treatment (brentuximab and combination chemotherapy)
description
Given IV
name
Brentuximab Vedotin
other Names
ADC SGN-35
Adcetris
Anti-CD30 Antibody-Drug Conjugate SGN-35
Anti-CD30 Monoclonal Antibody-MMAE SGN-35
Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35
cAC10-vcMMAE
SGN 35
SGN-35
SGN35
type
DRUG
arm Group Labels
Treatment (brentuximab and combination chemotherapy)
description
Given IV
name
Dacarbazine
other Names
4-(Dimethyltriazeno)imidazole-5-carboxamide
5-(Dimethyltriazeno)imidazole-4-carboxamide
Asercit
Biocarbazine
Dacarbazina
Dacarbazina Almirall
Dacarbazine - DTIC
Dacatic
Dakarbazin
Deticene
Detimedac
DIC
type
DRUG
arm Group Labels
Treatment (brentuximab and combination chemotherapy)
description
Given IV
name
Doxorubicin Hydrochloride
other Names
5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI)
ADM
Adriacin
Adriamycin
Adriamycin Hydrochloride
Adriamycin PFS
Adriamycin RDF
ADRIAMYCIN, HYDROCHLORIDE
Adriamycine
Adriblastina
Adriblastine
Adrimedac
type
DRUG
arm Group Labels
Treatment (brentuximab and combination chemotherapy)
description
Correlative studies
name
Pharmacological Study
type
OTHER
arm Group Labels
Treatment (brentuximab and combination chemotherapy)
description
Given IV
name
Vinblastine
other Names
Vincaleucoblastine
VLB
type
DRUG

Study design

allocation

intervention Model

SINGLE_GROUP

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 41
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
Defined as the dose level at which =\< 1 of 6 subjects experience dose limiting toxicity.
measure
Maximal Tolerated Dose of Brentuximab Vedotin (Phase I)
time Frame
28 days
description
2-year PFS is determined based on the Kaplan-Meier estimates and corresponding 95% confidence intervals based on standard errors using Greenwood's formula.
measure
2-year Progression-free Survival (PFS) (Phase II)
time Frame
2 years

secondary Outcomes

description
Number of Participants who had one or more adverse events
measure
Frequency of Adverse Events
time Frame
Up to 5 years
description
Number of participants who achieved a partial response per RECIST v1.0 criteria
measure
Partial Response Rate
time Frame
2 years
description
Number of participants who achieved a partial response per RECIST v1.0 criteria
measure
Partial Response Rate
time Frame
5 years
description
Number of participants who experienced a complete response per RECIST v1.0 criteria
measure
Complete Response Rate
time Frame
2 years
description
Number of participants who achieved a complete response per RECIST v1.0 criteria
measure
Complete Response Rate
time Frame
5 years
description
Proportion of study participants who are alive at 2 years estimated using the Kaplan-Meier survival function
measure
2-year Overall Survival
time Frame
2 years
description
Proportion of participants who are alive at 5 years using a Kaplan-Meier estimate
measure
Overall Survival
time Frame
5 years
description
Proportion of participants who are alive and progression-free at 2 years
measure
Event-free Survival
time Frame
2 years
description
Binomial probabilities and their 95% confidence intervals will be used to estimate the response rates (i.e., partial response rate, complete response rate, overall response rate) and event free survival at 2 and 5 years of AVD and brentuximab vedotin for a treatment of patients with stage III/IV HIV-associated Hodgkin lymphoma.
measure
Event-free Survival
time Frame
5 years
description
CD4 counts (absolute) at visit 4 (cycle 5)
measure
CD4 Counts
time Frame
5 months
description
Absolute CD8 counts at cycle 5
measure
CD8 Counts
time Frame
5 months
description
HIV viral load (detectable)
measure
Viral Load
time Frame
5 months

Full study description

brief Summary: This pilot phase I/II trial studies the side effects and the best dose of brentuximab vedotin when given together with combination chemotherapy and to see how well they work in treating patients with stage II-IV human immunodeficiency virus (HIV)-associated Hodgkin lymphoma. Brentuximab vedotin is a monoclonal antibody, called brentuximab, linked to a chemotherapy drug called vedotin. Brentuximab attaches to CD30-positive cancer cells in a targeted way and delivers vedotin to kill them. Drugs used in chemotherapy, such as doxorubicin hydrochloride, vinblastine sulfate, and dacarbazine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving brentuximab vedotin together with combination chemotherapy may kill more cancer cells.
detailed Description: PRIMARY OBJECTIVES I. To identify the maximum tolerated dose (MTD) of brentuximab vedotin when combined with the doxorubicin hydrochloride, vinblastine sulfate, and dacarbazine (AVD) chemotherapy regimen in the treatment of HIV-associated stage II-IV Hodgkin lymphoma. (Phase I) II. Establish an estimate of the two-year progression-free survival (PFS) for participants with HIV-associated stage II-IV Hodgkin lymphoma when treated using brentuximab vedotin plus the AVD chemotherapy regimen. (Phase II) SECONDARY OBJECTIVES: I. To evaluate the toxicity of AVD and brentuximab vedotin with highly active antiretroviral therapy (HAART). II. To estimate the partial response (PR) rate, complete response (CR) rate, overall survival (OS), and event free survival (EFS) at 2 and 5 years. III. To evaluate the effect of AVD and brentuximab vedotin on cluster of differentiation (CD)4 and CD8 counts after cycle 1, 4, at the end of therapy, and every 3 months after treatment completion for one year. IV. To investigate the prognostic value of fludeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) scans at baseline, after cycle 2, and at treatment completion, with respect to 2-year progression free survival. V. To evaluate HAART status at baseline and to correlate this with tumor response to therapy and OS and PFS. VI. To characterize the histologic subtypes in HIV-Hodgkin lymphoma (HL) in the highly active antiretroviral therapy (HAART) era. VII. To assess the neurotoxicity of HAART in combination with AVD and brentuximab vedotin. VIII. To evaluate effect of AVD and brentuximab vedotin on viral load after cycles 1, 4, at the completion of therapy, and every 3 months after treatment completion for one year. IX. To perform pharmacokinetic and immunogenicity studies to determine drug levels during therapy. X. To perform micro ribonucleic acid (miRNA) profile analysis on the HIV-HL tumor specimens and to correlate miRNA expression with OS, PFS, tumor response to therapy, histologic subtype of HIV-HL, and HIV disease characteristics. XI. To perform tissue microarray analysis on HIV-HL tumor specimens and to correlate the markers studied with OS, PFS, and tumor response to therapy. XII. To identify Epstein-Barr virus (EBV)-associated tumor derived deoxyribonucleic acid (DNA) in the plasma of study participants and to correlate these levels during therapy with disease response and OS. (Phase II) XIII. To identify cytokines in the plasma of participants during therapy that can be used as tumor and prognostic markers. (Phase II) XIV. To assess latent and expressed HIV reservoirs before, during, and post chemotherapy. To understand how cytotoxic chemotherapeutic agents affect HIV expression. OUTLINE: This is a phase I, dose-escalation study of brentuximab vedotin followed by a phase II study. Patients receive doxorubicin hydrochloride intravenously (IV), vinblastine sulfate IV, and dacarbazine IV on days 1 and 15. Patients also receive brentuximab vedotin IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for 3 years.

Source references

references

citation
Rubinstein PG, Moore PC, Bimali M, Lee JY, Rudek MA, Chadburn A, Ratner L, Henry DH, Cesarman E, DeMarco CE, Costagliola D, Taoufik Y, Ramos JC, Sharon E, Reid EG, Ambinder RF, Mitsuyasu R, Mounier N, Besson C, Noy A; AIDS Malignancy Consortium; Lymphoma Study Association. Brentuximab vedotin with AVD for stage II-IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial. Lancet Haematol. 2023 Aug;10(8):e624-e632. doi: 10.1016/S2352-3026(23)00157-6.
pmid
37532416
type
DERIVED
citation
Rubinstein PG, Moore PC, Rudek MA, Henry DH, Ramos JC, Ratner L, Reid E, Sharon E, Noy A; AIDS Malignancy Consortium (AMC). Brentuximab vedotin with AVD shows safety, in the absence of strong CYP3A4 inhibitors, in newly diagnosed HIV-associated Hodgkin lymphoma. AIDS. 2018 Mar 13;32(5):605-611. doi: 10.1097/QAD.0000000000001729.
pmid
29280762
type
DERIVED

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-dfca5b82e395075fcf6d
requested nct id
NCT01771107
primary nct id
NCT01771107
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=AIDS-Related+Lymphoma&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
a8469a8cca20a75ce4fa980eaab4ff20f62c99f2a2e732f1bd42590d1d5dbe14
payload sha256
54a36ebf349946076e9ab4458c49ddd3d39ac9be2b82dd3e1de126a810c8e8cb
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-dfca5b82e395075fcf6d
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT01771107
occurrences
context exact
NCT01771107
end
11
exact text
NCT01771107
start
0
offset unit
unicode_code_points
query cond
AIDS-Related Lymphoma
query disease state id
ds-aids-related-lymphoma
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-aids-related-lymphoma-000.json
source file sha256
a8469a8cca20a75ce4fa980eaab4ff20f62c99f2a2e732f1bd42590d1d5dbe14
source json pointer
/studies/25/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
d7f13b489aa424f8fabfcf69873c5ab785feb6e79777c6a91c2e4636f0271729
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=AIDS-Related+Lymphoma&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice